CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 49 enrolled
Drug / intervention
Lenalidomide +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01351896
NCT01351896Phase 2Active
CompareCT.gov

Phase II Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) With High-Risk Genomic Features

National Cancer Institute (NCI)·interventional·Posted May 11, 2011·Updated May 27, 2026

In Brief

A Phase 2 clinical trial evaluating Biospecimen Collection, Bone Marrow Aspiration, and 4 other interventions for Ann Arbor Stage I Small Lymphocytic Lymphoma and 8 related conditions. Active but no longer recruiting, targeting 49 participants across 1 site.

Detailed Summary

This phase II trial studies the effect of lenalidomide and vaccine in treating patients with early-stage asymptomatic chronic lymphocytic leukemia or small lymphocytic lymphoma. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. It may also stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnn Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
20112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 11, 2011
Enrollment StartNov 2, 2011
Primary CompletionJul 8, 2024
Study CompletionMay 6, 2027
TodayJul 2, 2026
Enrollment to primary: 12.7 yearsPosted 15.1 years ago

Interventions

Biospecimen Collectionprocedure

Undergo blood sample collection

Bone Marrow Aspirationprocedure

Undergo bone marrow aspiration

Bone Marrow Biopsyprocedure

Undergo bone marrow biopsy

Computed Tomographyprocedure

Undergo CT

Lenalidomidedrug

Given PO

Pneumococcal Polyvalent Vaccinebiological

Given IM (concurrently or sequentially)